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Abstract
Von Hippel-Lindau disease is an uncommon autosomal dominant inherited disease with the
responsible gene located in the short arm of chromosomal 3 within the locus 3p25-26. Clinically it
is characterized by retinal and central nervous system hemangioblastomas, visceral cysts or tumors
including renal cell carcinoma, neural crest origin tumors (most commonly pheochromocytoma) and
endolymphatic sac tumour. Familial screening and counseling are important. We reported a case of
a young man suffering from von Hippel-Lindau disease and it is now relatively asymptomatic on
peritoneal dialysis. High level of suspicion and a detailed family history are necessary to attain
the diagnosis.
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CASE REPORT
Our patient is a 25-year-old gentleman who first
presented in 1990 with impairment of left-sided visual
acuity. Retinal hemorrhage was diagnosed and he
underwent repeated cryosurgery. However, salvage was
unsuccessful and he ended up with blindness in left eye.
Since then he defaulted follow-up, and not until 1993
did he present again with right-sided retinal hemorrhage
that rendered him totally blind in late 1993.
Three years later in 1996, he presented to the surgical
department for painful left testicular swelling.
Ultrasonogram (USG) revealed multiple cystic lesions
of the left epididymis. The epididymal mass was excised
and histologically diagnosed to be papillary cystadenoma
(Fig. 1).
After the operation, he was asymptomatic for about 6
months and then started to complain of vague abdominal
discomfort and right-sided loin pain in August 1996. USG
and computed tomogram (CT) of abdomen showed a
heterogeneous mass over the right kidney. Radical right
nephrectomy was done in January 1997, and histology
confirmed right renal cell carcinoma (Fig. 2). Serial USG
and CT were performed for assessment and in September
1998, USG showed a suspicious space occupying lesion
of 1.5 x 2 cm in size over the left kidney (Fig. 3), and CT
guided fine needle aspiration cytology diagnosed renal
cell carcinoma. Left nephrectomy was done in March
1999 and thereafter he was referred to us and was started
on renal replacement therapy, as he was then anephric
after the operation.
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Going into more of his history, we found that his father
also had renal cell carcinoma and left nephrectomy, and
one of his sisters who had pancreatic cysts and cerebellar
hemangioblastoma was followed up in the surgical and
the neurosurgical departments (Fig. 4). Therefore, he
suffered from a familial disease causing renal cell
carcinoma, recurrent retinal hemorrhage, visceral cystic
lesions and also central nervous system (CNS)
involvement. The diagnosis was consistent with von
Hippel-Lindau syndrome. After the diagnosis was made,
his younger sister was arranged for regular screening,
and all the screening tests were negative. He has been
on helper continuous ambulatory peritoneal dialysis for
more than 1 year rather uneventfully.
DISCUSSION
In 1894, von Hippel, a German ophthalmologist first
observed a familial nature of retinal hemangioblastomas,
and Arvid Lindau, a Swedish ophthalmologist from Lund,
made the critical observations that cerebellar and retinal
hemangioblastomas are part of a larger "angiomatous
lesion of the CNS" with or without visceral
manifestations, and that the condition is heritable. In
Table 1.  Diagnostic criteria and classification for von Hippel-Lindau
disease.
(I) Family history of retinal or CNS hemangioma/hemangioblastoma
(II) No clear family history
For group (I) 1 hemangioblastoma or 1 visceral lesions
(renal, pancreas, adrenal, epididymis, etc)
For group (II) ≥ 2 hemangioblastomas or
1 hemangioblastoma + 1 visceral lesion
Type I vHL disease
Type II vHL disease + pheochromocytoma
A. Pheochromocytoma and retinal and CNS hemangioblastomas
B. Pheochromocytoma, retinal and CNS hemangioblastomas,
renal cancers and pancreatic lesions
Figure 1. Papillary folds lined by columnar epithelium with clear
cytoplasm and supported by thin connective tissue core.
Figure 2. Small nodule of carcinoma within normal renal cortex -
the carcinoma is composed of clear cells with small dark nuclei.
Figure 3. CT scan abdomen showing absence of right kidney due
to previous nephrectomy. A mass of soft tissue density is seen at
hilum of left kidney.
Figure 4. Family tree.
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1964, Melmon and Rosen summarized these results and
codified the term "von Hippel-Lindau" syndrome in
memory of the two ophthalmologists who first described
this condition (1).
Von Hippel-Lindau disease is a rare hereditary disease.
Its estimated prevalence is between one per 35,000 and
one per 40,000 in the United States. It is inherited as
autosomal dominant. The von Hippel-Lindau gene is a
tumor-suppressing gene and is located in the short arm
of chromosome 3 within the locus 3p25-26 (2). Clinical
features mainly include four categories, namely, 1. retinal
and CNS lesions, 2. visceral cysts of tumors, 3. neural
crest origin tumors including pheochromocytoma,
ectopic paragangliomas and amine precursor uptake and
decarboxylation cells tumour (Apudoma), and 4.
endolymphatic sac tumor (3).
Clinical diagnostic criteria for von Hippel-Lindau
syndrome were proposed by Melmon and Rosen (Table
1), and the National Cancer Institution classification of
von Hippel-Lindau disease distinguishes two types:
type I  is  von Hippel-Lindau disease without
pheochromocytoma, and type II is von Hippel-Lindau
disease with pheochromocytoma, and is further
subdivided into two types (Table 1) (4).
Retinal hemangioblastoma, present in up to 45% to 59%,
is the most frequent presentation in von Hippel-Lindau
syndrome. Half of them are bilateral. Only 5% of cases
are discovered before the age of 10 and new lesions may
develop within 2 years of presentation. Therefore
frequent monitoring is necessary. Clinically, if the lesions
are situated peripherally in the retina, they are relatively
asymptomatic. Hemorrhage is common and can lead to
profound visual loss. Early detection and aggressive use
of photocoagulation is the only effective mode of
preventing blindness. CNS hemangioblastomas usually
occur in the cerebellum, the spine or the medulla. They
occur in 44% of von Hippel-Linda patients, and are
usually discovered at a mean age of 29 years (5).
Renal cysts are present in 59% to 63% of the patients,
and renal cell carcinoma occurs in up to 24% to 45% of
cases. For renal disease, it is unusual to have the von
Hippel-Lindau syndrome to be the first manifestation.
The mean age of renal cell carcinoma presentation is 37
years, which is much earlier than that of sporadic renal
cell carcinoma (mean age 57 years). Both the renal cysts
and solid tumor grow, but neither the cyst size nor the
number correlates with malignant potential. Other less
common renal lesions include renal angiomas and renal
adenomas (6). CT scan is more sensitive than USG for
diagnosing renal lesions, especially for small tumors
smaller than 2 cm. Magnetic resonance (MR) imaging is
also a useful imaging technique especially in patients
with renal failure (7).
For patients who present late with renal tumors,
nephrectomy is the only option. But for those with small
asymptomatic lesions, it is recommended that the lesion
is closely monitored until it attains 2 cm to 3 cm, when
nephron-sparing surgery can be performed. This
approach is designed not to cure but rather to minimize
the risk of metastasis while delaying the start of renal
replacement therapy. Good results are observed with
enucleation and partial nephrectomy, but recurrences at
new sites are not infrequent. Therefore, the patient must
be closely followed up after surgery with CT scan every
6 months for 2 years, followed by lifetime annual
screening (3). There is no difference between peritoneal
and hemodialysis in terms of morbidity and mortality
for such patients.
Renal transplantation is not contraindicated, but
immunosuppressive therapy has been shown in some
studies to promote tumor growth. Patients with
malignancy who undergo renal transplantation will have
higher mortality and complication rates than those on
hemodialysis. Therefore, a delay of at least 1 year is
usually advocated between nephrectomy and
transplantation to ensure that no metastasis will occur,
and careful screening of other malignancy is necessary
prior to transplantation. With the advances in human
genetics, living related renal transplantation is possible
after genetic screening of siblings.
Clinical screening for family members with possible von
Hippel-Lindau disease is important. The von Hippel-
Lindau disease gene belongs to the family of tumor
suppressor genes. Several "franking markers", DNA
probes that are located proximal or distal to the von
Hippel-Lindau gene, are discovered at the 3p25-26 locus.
This discovery of DNA markers and specific genetic
mutations means that asymptomatic family members can
be screened for von Hippel-Lindau disease with a blood
Table 2.  NIH clinical screening for vHL syndrome.
Age (year) Recommendation
Infancy Annual exam. (physical and eye examination)
2 Urinary catecholamines 1-2 yearly
11 * Biannual MR imaging brain and spine;
* Annual USG abdomen (if renal cysts or
   tumour + ve, then CT scan 6 monthly)
20 Change from yearly USG to yearly CT scan
60 If no evidence of von Hippel-Lindau disease,
MR imaging 3-5 yearly, and
   CT scan every other year.
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test and that von Hippel-Lindau disease can be confirmed
or ruled out in patients who have already been screened
with imaging tests and have nonspecific findings such as
renal cysts. However, in up to 20% of patients, the exact
mutation has not been identified. Moreover, the
mechanism of the blood test is such that not every
individual without a family history of von Hippel-Lindau
disease can be tested: A minimum of two affected family
members is needed for the DNA markers to be useful in
linkage analysis. At present, up to 14% of families will
be "uninformative" with respect to these DNA markers.
Recombination, the exchanging of one segment of the
allele for the homologous contralateral segment, occurs
with a 1% frequency at this locus and will produce false
negative results. Thus, patients with negative or borderline
results of genetic tests should still be tested for the major
complications of von Hippel-Lindau disease.
For those members with a negative DNA and clinical
screening, they are unlikely to be vHL carriers and
therefore do not need frequent monitoring. For those with
positive DNA but negative clinical screening, they are
likely to be von Hippel-Lindau carriers and they require
routine serial screening (8). And for those individuals
having borderline DNA screening test results or that DNA
screening is not available, they are treated as if they were
carriers, and clinical screening should continue until they
are at least 60 years of age (9). The recommended clinical
screening for von Hippel-Lindau disease suggested by
the National Institutes of Health  is listed in table 2 (3).
In conclusion, von Hippel-Lindau disease is a rare
autosomal dominant inherited form of disease that
involves multiple organs. It is essential to have
multidisciplinary work and good coordination between
nephro log i s t s ,  su rgeons ,  oph tha lmolog i s t s ,
neurosurgeons and genetic workers in terms of patient
management, family screening as well as genetic
counseling.
REFERENCES
1. Melmon K, Rosen S. Lindau's disease. Am J Med 1964;36:595-
617.
2. Christopher A Friedrich. Von Hippel Lindau disease. A pleomorphic
condition. Am Cancer Society 2nd National conference on cancer
genetics. June 1999.
3. Choyke PL. Von Hippel Lindau disease: Genetics, clinical and
imaging features. Radiology 1995;194:629-642.
4. Yates JRW, Maher ER. Clinical features and natural history of Von
Hippel Lindau disease. Q J Med 1990;77:1151-1163.
5. Cavenee WK. Predic t ion of  fami l ia l  pred ispos i t ion to
retinoblastomas. N Engl J Med 1986;314:1201-1207.
6. Maher ER. Von Hippel Lindau disease (review). Medicine 1997;76:
381-391.
7. Choyke PL. Radiologic screening for visceral manifestations of von
Hippel Lindau disease. Radiology 1990;174:815-820.
8. Maher ER. Von Hippel Lindau disease: a genetic study. J Med
Genetic 1991;28:443-447.
9. Gladys M. Screening for von Hippel Lindau disease by DNA
polymorphism analysis. JAMA 1992:267:9;1226-1231.
